Israeli drugmaker XTL Biopharmaceuticals says that the USA's Cubist Pharmaceuticals has released strong data from a recently-concluded Phase II study of its canddiate treatment for hepatitis B virus, HepeX-B, which it licensed to Cubist in 2004.
In the Phase II evaluation, the agent was studied as maintenance therapy to prevent reinfection with HBV in patients with liver transplants. Liver transplant patients treated with monthly infusions of 20mg or 40mg HepeX-B versus 5000 IU of HBIg showed that those on either dose of HepeX-B experienced no evidence of reinfection. The data also showed fewer and less serious adverse experiences with HepeX-B compared to the HBIg group, although this was not statistically significant given the number of patients in the trial. Cubist says it will review Phase II results with the US Food and Drug Administration early in 2006.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze